Treat-and-extend versus every-other-month regimens with aflibercept in age-related macular degeneration
Treat-and-extend versus every-other-month regimens with aflibercept in age-related macular degeneration
复制标题
DOI：
10.1111/aos.13607
复制
发表时间：
2018-05-01
影响因子：
3.4
通讯作者：
Tanihara, Hidenobu
中科院分区：
文献类型：
--
作者：
Haga, Akira;Kawaji, Takahiro;Tanihara, Hidenobu
PurposeTo比较玻璃体内注射aflibercept治疗并延长（TAE）和每隔一个月（2M）方案治疗日本湿性年龄相关性黄斑变性（AMD）患者的1年结局。主要结果测量是在第52周时维持最佳矫正视力（BCVA）的眼睛比例[
PurposeTo compare the 1-year outcomes of treat-and-extend (TAE) and every-other-month (2M) regimens with intravitreal aflibercept in Japanese wet age-related macular degeneration (AMD) patients.MethodsProspective, multicenter, randomized clinical trial. The primary outcome measure was the proportion of eyes in which the best-corrected visual acuity (BCVA) was maintained at week 52 [with a loss of